Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byIpsen
Price$206M
Date7/2013

General Information

Offices

Abingdon, GBR
Units 4-10, The Quadrant
Barton Lane
Abingdon, OX14 3YS, GBR

People

Member of the Board of Directors

Funding

Tags

Syntaxin

Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company’s proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.

Recent Milestones

Videos

Screenshots

Syntaxin screenshot
Above: Syntaxin
Uploaded: 3/12/10

Sources

  1. Ipsen to Acquire Syntaxin for $206 (genengnews.com) [edit]
  2. EDGAR [edit]
  3. Syntaxin Raises $32M to Advance Development of Novel Drug Pipeline (syntaxin.com) [edit]
  4. VCs inject $29M into Syntaxin, $11.5M into Ceregene (fiercebiotech.com) [edit]
Edit This Page
Last Edited 9/9/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy